• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Pacific Biosciences Has Made a Bottom Pattern: Prices to Watch

The stock bottomed in June/July and have worked higher.
By BRUCE KAMICH
Dec 06, 2022 | 10:26 AM EST
Stocks quotes in this article: PACB

Pacific Biosciences of California Inc. (PACB) is a biotechnology company that develops and manufactures systems for gene sequencing and biological observation. Let's keep it simple, though, with a check of the stock's charts and indicators.

In this daily bar chart of PACB, below, we can see a "classic" saucer bottom formation. The shares bottomed in June/July and have worked higher. Now PACB trades above the rising 50-day moving average line and above the bottoming 200-day moving average line. A bullish golden cross buy signal can be seen in November with the 50-day line crossing above the 200-day line.

The On-Balance-Volume (OBV) line has improved from a low in June and tells me that buyers of PACB have been more aggressive for the past five months. The Moving Average Convergence Divergence (MACD) oscillator is bullish.

 
In the weekly Japanese candlestick chart of PACB, below, we see a promising picture. The shares made a major decline/correction in 2021 but then a bottom pattern in 2022. Prices have rallied and now trade above the bottoming 40-week moving average line. The weekly candles are not showing us a top reversal and few upper shadows.
 
The weekly trading volume has been active since May. The weekly OBV line shows a strong rise from June telling us that buyers are more aggressive. The MACD oscillator is crossing the zero line for an outright buy signal.
 
 
 In this daily Point and Figure chart of PACB, below, we can see an upside price target in the $26 area.
 
 
 
 
In this weekly Point and Figure chart of PACB, below, we can see the same $26 price target as the daily chart.
 
 
Bottom-line strategy: Success in the biotechnology field can come and go so traders need to keep that in mind when they go long. Traders could long PACB around $10 risking to $7. The $26 area is our price target for now.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Drug Approvals | Investing | Stocks | Technical Analysis | Biotechnology | Health Care Equipment & Services | Life Sciences

More from Stocks

Fast Food Might Offer Investors a Quick Buck

Bob Lang
Feb 7, 2023 5:15 PM EST

Let's see how these restaurants may be settling into a profit sweet-spot amid inflation's ups and downs.

Giddy Market Gets Powell Happy

James "Rev Shark" DePorre
Feb 7, 2023 4:33 PM EST

The euphoric reaction to the Fed among investors makes little sense -- but adds to the market volatility.

When It Comes to Politics and ETFs, If You Can't Beat 'Em, Join 'Em

Mark Abssy
Feb 7, 2023 2:17 PM EST

Surprise! Lawmakers, no matter the party, are not exempt from insider-trading laws, just like the rest of us. But we can all invest in these two new exchange-traded funds.

Is FMC Corp Facing a Downward Correction?

Bruce Kamich
Feb 7, 2023 12:55 PM EST

Let's see what the charts look like.

It's Decision Time for Bulls and the Market

James "Rev Shark" DePorre
Feb 7, 2023 11:45 AM EST

The market is at a very important juncture.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:22 AM EST REAL MONEY

    LIVE EVENT: Bruce Kamich and Todd Campbell Share Their Stock Market Insights

    This Monday, Feb. 6 at 12 p.m., our very own exper...
  • 02:58 PM EST REAL MONEY

    Sarge Guilfoyle Breaks Down the Jobs Report, Fed Policy and Stocks!

    Watch it here!
  • 11:35 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading an Irrational Market
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login